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Stem cells are undifferentiated cells that are present in the embryonic, fetal, and adult stages of life and give rise to differentiated
cells that make up the building blocks of tissue and organs. Due to their unlimited source and high differentiation potential, stem
cells are considered as potentially new therapeutic agents for the treatment of infertility. Stem cells could be stimulated in vitro
to develop various numbers of specialized cells including male and female gametes suggesting their potential use in reproductive
medicine. During past few years a considerable progress in the derivation of male germ cells from pluripotent stem cells has been
made. In addition, stem cell-based strategies for ovarian regeneration and oocyte production have been proposed as future clinical
therapies for treating infertility in women. In this review, we summarized current knowledge and present future perspectives and
challenges regarding the use of stem cells in reproductive medicine.
1. Introduction
Nearly 72.4 million people or 15% of couples experience
fertility problems [1]. For couples and clinicians, a diagnosis
of infertility signals the start of investigations and possible
treatment. Infertility, defined as failure to conceive a clinically
detectable pregnancy after >12 months of unprotected inter-
course, is a common condition, reported by 1 in 6 couples
[1, 2]. As infertility is a heterogeneous condition, caused
by various underlying pathologies, it is possible that some
of the mechanisms leading to infertility also play a role in
the etiology of this outcome [3–5]. In recent years, several
advancements have been made in assisted reproduction
treatment and now more than 80% of couples experiencing
infertility issues can conceive a child [6].
Due to their unlimited source and high differentiation
potential, stem cells are considered as potentially new ther-
apeutic agents for the treatment of infertility. In this review,
we will summarize current knowledge regarding the use of
stem cells in reproductive medicine.
2. Stem Cells: A Novel Hope in
Cell-Based Therapy
Stem cells are undifferentiated cells that are present in the
embryonic, fetal, and adult stages of life and give rise to
differentiated cells that are building blocks of tissue and
organs (Table 1). In the postnatal and adult stages of life,
tissue-specific stem cells are found in differentiated organs
and are instrumental in repair following injury to the organ.
The major characteristics of stem cells are (a) self-renewal
(the ability to extensively proliferate), (b) clonality (usually
arising from a single cell), and (c) potency (the ability to
differentiate into different cell types) [7, 8]. Totipotent or
omnipotent cells are the most undifferentiated cells and
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Table 1: Characteristics of stem cells used in stem cell-based therapy of infertility.
ESCs MSCs Stem cell fromextraembryonic tissues iPSCs Spermatogonial stem cells
Derived from inner cell
mass of the blastocyst
Derived from bone
marrow, adipose tissues,
bone, Wharton’s jelly,
umbilical cord blood, and
peripheral blood
Derived from amnion,
chorion, placenta, and
umbilical cord
Derived from somatic cells Derived from testiculartissues
Pluripotent Multipotent Multipotent Pluripotent Pluripotent
These cells can
differentiate into cell
types of all three germ
layers
These cells can
differentiate into
mesoderm-derived tissues
(adipose tissues, bon,
cartilage, and muscle)
These cells can
differentiate into
adipocytes, endothelial
cells, hepatocytes,
osteocytes, myocytes, and
neurons
These cells can
differentiate into cell types
of all three germ layers
These cells can
differentiate into cell types
of all three germ layers
Prolonged proliferation
Degree of proliferation
depends on the tissue
from which these cells
were isolated
Degree of proliferation
depends on the tissue
from which these cells
were isolated
Prolonged proliferation Difficult to be maintainedin cultures
Indefinite self-renewal
potential Limited self-renewal Limited self-renewal
Indefinite self-renewal
potential
Self-renewal ability to go
through numerous cell
divisions while
maintaining the
undifferentiated state
High telomerase activity Low telomerase activity Low telomerase activity High telomerase activity High telomerase activity
Immortal; cell lines
remain intact for long
periods of time and
produce endless
numbers of cells
Production of limited
number of cells
Production of limited
number of cells
Immortal; cell lines
remain intact for long
periods of time and
produce endless numbers
of cells
—
These cells are not
immune privileged
These cells have
immunomodulatory
characteristics
— These cells are notimmune privileged
These cells are not
immune privileged
are found in early development. A fertilized oocyte and
the cells of the first two divisions are totipotent cells, as
they differentiate into both embryonic and extraembryonic
tissues, thereby forming the embryo and the placenta [9].
Pluripotent stem cells are able to differentiate into cells that
arise from the 3 germ layers—ectoderm, endoderm, and
mesoderm—from which all tissues and organs develop [10].
Commonly, stem cells are derived from two main sources:
early embryos (embryonic stem cells (ESCs)) and adult tissue
(adult stem cells).
ESCs are pluripotent stem cells derived from the inner
cell mass of the blastocyst [11]. The essential characteristics
of ESCs include derivation from the preimplantation embryo,
prolonged proliferation in their pluripotent state, and stable
developmental potential to form derivatives of all three
embryonic germ layers [11].
Mesenchymal stem cells (MSCs) are one of themost com-
mon adult, multipotent stem cells [12]. They can be derived
from a variety of tissues including bone marrow, adipose tis-
sue, bone, Wharton’s jelly, umbilical cord blood, and periph-
eral blood [13]. MSCs are adherent to cell culture dishes and
are characterized by specific surface cell markers.MSCs show
variable levels of expression of several molecules, CD105
(SH2), CD73 (SH3/4), stromal antigen 1, CD44, CD166
(vascular cell adhesion molecule), CD54/CD102 (intracellu-
lar adhesion molecule), and CD49 (very late antigen), and
lack the expression of surface markers characteristic for
HSCs (CD14, CD34, CD45, and CD11a/LFA-1), erythrocytes
(glycophorin A), and platelet and endothelial cell (CD31).
MSCs are able to differentiate into mesoderm-derived tissue
such as adipose tissue, bone, cartilage, and muscle [13–
16]. Recently, MSCs were differentiated into neuronal tissue
which is derived from the ectoderm. This is an example of
transdifferentiation, that is, when a cell from one germ layer
(mesoderm) differentiates into neuronal tissue (ectoderm)
[17].
Stem cells can also be derived from extraembryonic
tissues (amnion, chorion, placenta, and umbilical cord)
[18]. Amnion and chorion contain stromal cells that dis-
play characteristics and differentiation potential similar to
bone marrow-derived MSCs and are able to differentiate
into adipocytes, endothelial cells, hepatocytes, osteocytes,
myocytes, and neurons [7, 18]. Placental-derived stem cells
have the capacity to differentiate into ectodermal, meso-
dermal, and endodermal cell types, while umbilical cord
matrix stem cells, after transplantation, enhanced muscle
regeneration in mouse model of severe muscle damage and
promoted blood vessel formation and neurological function
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Table 2: Potential advantages and disadvantages of stem cells in regenerative medicine.
Stem cells Advantages Disadvantages
ESCs Pluripotent; high telomerase activity
Ethical concerns; malignant potential; difficult to
control; may require many steps to differentiate into
desired cell type; immune rejection
MSCs No ethical or moral concerns; low malignant potential;avoiding allogeneic immune rejection
Limited flexibility; multipotent; difficulty to be
maintained in cell culture for long periods
Stem cell from
extraembryonic tissues
No ethical or moral concerns; reducing risk of
tumorigenicity Limited flexibility; multipotent
iPSCs No ethical or moral concerns; patient-specific cells Use of viral vectors to introduce genes; malignantpotential
Spermatogonial stem
cells No ethical or moral concerns
Relatively small numbers in testis; difficulty to be
maintained in cultures; immune rejection
in animal models of ischaemic brain disease [18]. The main
advantage of stem cells derived from extraembryonic tissues
is the efficient isolation from tissues normally discarded at
birth avoiding ethical concerns that plague the isolation of
human embryonic stem cells [7] (Table 2).
Recently, Takahashi and Yamanaka [19] generated
pluripotent cells by reprogramming somatic cells. These cells
are called induced pluripotent stem cells (iPSCs) and share
similar characteristics with ESCs: exhibiting morphology of
ESCs, expressing ESCs markers, having normal karyotype,
expressing telomerase activity, and maintaining the
developmental potential to differentiate into derivatives of
all three primary germ layers. Thus, iPSCs are adult cells that
have been genetically reprogrammed to an embryonic stem
cell-like state by being forced to express genes and factors
important for maintaining the defining properties of embry-
onic stem cells [20]. Transplantation of stem cells or their
derivatives into respective tissues or organs is considered
as one of the most promising remedies for many incurable
diseases. Unfortunately, immune compatible cells are hardly
obtainable for any given patient because of the specificity and
complexity of human immune system. In this regard, induced
pluripotent stem cells (iPSCs) and gene editing technologies
are believed to offer an unprecedented solution for obtaining
sufficient healthy autologous cells [21]. However, it should
be emphasized that, despite numerous technical advances
in the reprogramming technology, iPSCs apart from a very
small number of ongoing clinical studies are not yet ready for
transplanting into patients. Relatively little is known about
iPSCs molecular and functional equivalence to hESCs and
careful analysis of the genomic and epigenomic integrity of
human iPSCs is required before their therapeutic use.
Stem cells could be stimulated in vitro to develop
various numbers of specialized cells including male and
female gametes suggesting their potential use in reproductive
medicine.
3. Stem Cells Are Novel and Unlimited Source
for Male Gametes: True or False?
During past few years a considerable progress in the deriva-
tion of male germ cells from pluripotent stem cells has been
made [22–24].These studies provide a desirable experimental
model for elucidating underlying molecular mechanism of
male germ cell development and potential strategies for
producing haploid germ cells for the treatment of male
infertility.
Spermatogenesis is a complex process by which sper-
matogonial stem cells (SSC) self-renew and differentiate into
haploid spermatozoa. Inmammals, this process takes place in
the seminiferous tubules of testis, which provide a functional
niche for male germ cells [25] and involve three major stages:
mitosis, meiosis, and spermiogenesis [24]. Errors at any stage
of spermatogenesis can result in subfertility and infertility
[26].
SSC reside in adult testis and maintain spermatogenesis
and continual sperm production throughout a male’s lifespan
[27]. SSC are diploid cells that originate from less differ-
entiated primordial germ cells that migrate to the gonadal
ridges during embryogenesis [28]. SSC can be found in the
seminiferous tubule, lying near to the basement membrane
[29]. Several markers could be used for the identification
and isolation of SSC: spermatogonia-specificmarker Stra8 for
mouse SSC [30, 31], thymocyte antigen 1 (Thy-1), CD9, stage-
specific embryonic antigen-4 (SSEA4), 𝛽1 and 𝛼6 integrins
for rat SSC [32], SSEA4, and G-protein coupled receptor 125
(GPR125) for human SSC [33]. SSC are a potential tool for the
treatment ofmale infertility due to their ability to differentiate
intomale gametes in vitro and capacity to restoremale fertility
in vivo [34, 35]. SSC are adult stem cells, but SSC-derived cells,
called multipotent adult germline stem cells (maGSC), have
differentiation potential similar to ESCs. In vitro, maGSC
are able to spontaneously differentiate into derivatives of all
embryonic germ layers and are able to generate teratomas
after transplantation in immunodeficient mice [31]. Nolte
and coworkers showed that maGSC are able to undergo
meiosis and form haploid male germ cells in vitro [30]. An
important breakthrough for SSC-mediated spermatogenesis
wasmade byHermann and coworkers [35].They showed that
autologous and allogeneic SSC transplantations into the testes
of adult and prepubertal recipient macaques, which were
rendered infertile with alkylating chemotherapy, regenerate
spermatogenesis resulting in production of functional sperm.
These results strongly indicate SSC transplantation as a novel
and successful therapeutic tool for male infertility caused
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by chemotherapy before puberty [35]. Although SSC seem
to be a good candidate for the stem cell-based therapy of
male infertility, a low concentration of SSCs inmammal testis
and challenges associated with protocols for their isolation,
identification, and culturing have to be addressed before their
clinical use [29].
Hu¨bner et al. first reported the successful derivation
of gametes from mouse embryonic stem cells (ESCs) in
vitro [36]. Afterwards, different studies with mouse ESCs
have shown the ability to make functional spermatozoa
[37, 38] capable of giving rise to live offspring after use
of intracytoplasmatic injection [37]. Differentiation of male
germ cells from human ESC has also been demonstrated [39–
43]. Similarly, studies with human ESCs have revealed the
ability to differentiate in vitro into advanced spermatogenic
stages, including round spermatids which are not capable of
fertilizing oocytes in high-order mammals [22, 23].
Besides the fact that ESCs are genetically unrelated to
the patient in need of fertilization treatment, the isolation of
human ESCs is ethically controversial because it involves the
destruction of human embryos.The significant breakthrough
in stem cell biology, a discovery of patient-specific induced
pluripotent stem cells (iPSCs), may overcome these issues.
Recently, several studies have reported that bothmouse iPSCs
[24, 44, 45] andhuman iPSCs can differentiate intomale germ
cells [20, 21].
It has been verified that mouse iPSCs can form functional
spermatozoa [46, 47]. Functional assays have shown that
spermatozoa generated from iPSCswere capable of fertilizing
the oocytes after intracytoplasmatic injection and giving rise
to fertile offspring following embryo transfer [46]. So far,
functional male gametes from human iPSCs have not been
obtained.
There are two possible approaches in generating of male
germ cells from pluripotent stem cells: in vitro differentiation
into advanced, haploid cell products [20, 21] or combined
in vitro differentiation and in vivo transplantation [24, 48].
Generally, there are two methods to produce male gametes
from the pluripotent stem cells in vitro [20]: the monolayer
differentiation and the embryoid body (EB) formation [24,
44]. Direct differentiation onmonolayers of human fibroblast
ensures more consistent differentiation results compared
with EB formation [20].
Different growth factors or cytokines could induce
pluripotent stem cells into germ cells in vitro (Figure 1),
such as bone morphogenetic protein 4, stem cell factor,
epidermal growth factor, and forskolin, but most of in vitro
differentiation protocols include retinoic acid (RA) induction
[46, 49, 50]. It has been shown that RA, an active derivate
of vitamin A, regulates the timing of meiotic initiation in
mice [50, 51]. Some protocols include combination of RA and
testosterone [45] or subsequent exposure to differentiation
cocktail containing forskolin, human leukemia inhibiting
factor (LIF), bFGF, and CYP26 inhibitor R115866 [22].
Testosterone is required for spermatogenesis in vivo and
stimulates Sertoli cells to produce different growth factors,
including stem cell factor that promotes germ cell differen-
tiation [52]. Forskolin is involved in meiosis induction [53]
and induces germ cell proliferation by activation of cyclic
adenosine monophosphate [54]. LIF promotes survival and
proliferation of gonocytes [55], while bFGF helps balancing
self-renewal and differentiation of SSC [56]. R115866 acts by
suppressing the inhibitory effects of CYP26 on STRA8, the
meiosis regulator gene [51].
In some studies combination of in vitro differentiation
followed by in vivo transplantation was performed in order to
gain male gametes in advanced differentiation stages [24, 48]
(Figure 1). Most often, pluripotent stem cells are induced in
SSC-like stages in vitro and then transplanted into sterile
mice testis [24] or ectopic, into the dorsal region of the
mice, together with immature testicular cell suspension [44,
48]. It has been shown in several animal models that SSC-
like cells are capable of recolonizing the testis [34, 35] and
exhibit proper spermatogenesis [46]. A limiting step for stem
cell replacement therapy of infertility could be the damaged
somatic environment of the testis. If the somatic environment
is damaged it is not receptive to SSC transplantation and
thereby not able to restore patient fertility [57]. Ectopic
cotransplantation of SSC with testicular cells might be a way
to overcome this limitation but Yang et al. have reported that,
although iPSC-derived germ cells could reconstitute seminif-
erous tubules and settle at basement membrane, no further
differentiation was observed in reconstituted seminiferous
tubules [44].
4. Stem Cell-Derived Oocytes: Current
Knowledge and Future Perspectives
Stem cell-based strategies for ovarian regeneration and
oocyte production have been proposed as future clinical
therapies for treating infertility in women.
There has been a long-persisting dilemma regarding the
presence of ovarian stem cells in adult mammalian ovaries.
Several research studies claimed that they have identified
functional oogonial stem cells in the postnatal ovary of
several different species including humans and now there is
steadily increasing experimental evidence on their existence
[58]. An important breakthrough was made by Zou and
his coworkers who successfully established long-persisting
pluripotent/multipotent ovarian stem cell lines in neonatal
and adult mice [59]. They detected cells residing within the
ovarian surface epithelium of neonatal and adult mice that
were double positive for mouse vasa homologue (MVH) and
DNA marker 5-bromodeoxyuridine (BrdU) confirming that
these cells were of germ cell lineage and exhibited a replicative
potential (Figure 2).With passage in culture, the cells isolated
by Zou et al. were confirmed to have significant proliferative
capacity and expressed high telomerase activity, Oct4, and
Nanog. The cells were then marked using a retroviral vector
bearing green fluorescent protein (GFP) before being directly
delivered into the ovaries of adult female mice rendered
sterile by treatment with chemotherapy. Importantly, GFP+
follicles in various stages ofmaturationwere observed several
weeks later in the ovaries of the conditioned mice indicating
that isolated ovarian stem cells were capable of regenerating
functional oocytes when transplanted back into sterile recip-
ient mice [59] (Figure 2).
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Figure 1: Stem cell-derived male gametes. Several growth factors and cytokines are used for in vitro differentiation of pluripotent cells into
male gametes/SSC-like cells. The transplantation of stem cell-derived SSC-like cells in sterile mice results in proper spermatogenesis.
Recently, the work by White et al. has identified a rare
population of mitotically active germ cells in human ovaries
that can be purified and cultured in vitro to spontaneously
form oocytes [60]. These cells, named as germ stem cells
(GSCs), were isolated from reproductive-aged human ovaries
using fluorescence-activated cell sorting (FACS) with an
antibody against the carboxyl (−COOH) terminus of the
germ cell-specific marker Ddx4, which is expressed on the
cell surface of GSCs. Further, GSCs were capable of forming
oocyte-like structures and incorporating into follicles under
specific in vitro and in vivo conditions. This work highlights
a unique potential to generate oocytes in vitro from isolated
cells in reproductive-aged women who may have a depleted
follicle pool from such genetic defects as fragile X-associated
primary ovarian insufficiency. This recent advance, along
with those described above, highlights the unique method-
ologies being developed to combat female-factor infertility
representing a significant step towards the revolutionary idea
of neo-oogenesis in reproductive-aged women through the
isolation and characterization of germ stem cells.
However, despite the discovery of the potential germ stem
cells in mammalian ovaries, it remains uncertain whether
these cells exist and function in ovaries under physiological
conditions. Liu et al. concluded that active meiosis, neo-
oogenesis, and GSCs are unlikely to exist in normal, adult
human ovaries [61]. Findings published by Zhang et al.
contradict the results obtained by White et al. and Zhang et
al. used fluorescent proteins to identify GSCs in the ovaries
of mice, but these cells failed to divide or differentiate into
oocytes [62]. The scientific community has questioned both
the methods and significance of these studies. Supporters
of postnatal de novo oogenesis disagree with the study
conducted by Zhang et al. and state that the study investigated
oocytes and not GSCs in their applied experimental setting;
thus, the researchers never observedmitosis inDdx4-positive
cells since oocytes expressing cytoplasmicDdx4 donot divide
[63]. According to White et al., Ddx4 is found on the cell
surface of GSCs and thus enables FACS-based isolation of
livingGSCs fromadultmouse andhumanovaries [60].This is
in contrast to the opinion of Zhang et al., who argue thatDdx4
is expressed only in the cytoplasm and not on the cell surface
and hence FACS-based isolation of GSCs is problematic [64].
While the debate continues, only future experiments will help
to clarify this issue.
In the meantime, several studies were published regard-
ing the potential of pluripotent stem cells for differentiation
into oocytes. Eguizabal and coworkers managed to generate
haploid female cells from human pluripotent stem cells, but
neither of them resembled an oocyte nor is predicated to
possess a functional ooplasm capable of being fertilized [22].
However, the recent work by Hayashi et al. showed that
mouse stem cells could be differentiated in an in-vitro/in-
vivo system into oocyte-like cells that are capable of being
fertilized by spermatozoa and generating normal progeny
[65].This outstanding advancement further shows the ability
of pluripotent stem cells to differentiate into all cells of the
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Figure 2: Ovarian stem cells:isolation and regenerative potential.Ovarian stem cells (MVH+BrdU+ cells) residing within the ovarian surface
epithelium of neonatal and adult mice express high telomerase activity, Oct4, and Nanog and have a capacity to generate functional oocytes
when transplanted back into sterile recipient mice.
adult organism [64]. Whether the work by Hayashi and
colleagues can be adapted for human stem cells remains to
be seen, but this advancement is a critical step forward in
generating functional de novo oocytes from human iPSCs
obtained from female patients rendered sterile by medical
interventions, exposure to toxicants, or premature ovarian
failure [64].
5. Conclusions
Pluripotent stem cells open new perspectives in the treatment
of patients with azoospermia. Although the use of ESCs
is connected with many ethical concerns, there are no
ethical issues regarding the use of iPSCs. Moreover, ESCs are
genetically unrelated to the patients, while it may be possible
to get offspring with their own genetics by using iPSCs in
derivation of functional male gametes.
The potential clinical applications of putative ovarian
derived stem cells are apparent. The development of tech-
niques to prolong the window of fertility for women has
the ability to meet the needs of future populations and their
delay in childbearing. If a viable source of oocyte production
remains in infertile women with a reduced ovarian follicle
pool, for example, due to chemotherapy or advanced age, the
potential exists to restore fertility in these women. The iden-
tification of GSCs gives hope to these women and suggests
the potential for fertility restoration. In future, the protocols
for isolation and culture of GSCs must be optimized. In the
meantime, production of germ cells from ESCs or iPSCs is
another possible alternative for the treatment of infertility.
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